Edap Tms S.A. (NASDAQ:EDAP) Short Interest Up 163.4% in December

Edap Tms S.A. (NASDAQ:EDAP) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 93,243 shares, a growth of 163.4% from the November 30th total of 35,401 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 71,663 shares, the short-interest ratio is currently 1.3 days. Based on an average daily volume of 71,663 shares, the short-interest ratio is currently 1.3 days. Approximately 0.2% of the company’s stock are short sold.

Edap Tms Stock Performance

EDAP stock traded up $0.43 during mid-day trading on Friday, reaching $3.40. The company had a trading volume of 109,781 shares, compared to its average volume of 61,671. Edap Tms has a one year low of $1.21 and a one year high of $3.45. The stock has a market capitalization of $127.13 million, a P/E ratio of -5.96 and a beta of -0.15. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.04. The stock’s 50-day simple moving average is $2.40 and its two-hundred day simple moving average is $2.05.

Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.11. The firm had revenue of $16.29 million for the quarter, compared to the consensus estimate of $15.05 million. Edap Tms had a negative net margin of 30.95% and a negative return on equity of 61.60%. Research analysts anticipate that Edap Tms will post -0.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on EDAP. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edap Tms in a research note on Monday. Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 target price on shares of Edap Tms in a research report on Thursday, November 6th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Edap Tms has an average rating of “Hold” and a consensus target price of $8.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Simplicity Wealth LLC bought a new stake in Edap Tms in the second quarter valued at $54,000. Sage Mountain Advisors LLC acquired a new position in shares of Edap Tms during the second quarter valued at $165,000. Scoggin Management LP bought a new position in shares of Edap Tms in the 1st quarter valued at about $686,000. Finally, Banque Transatlantique SA boosted its stake in Edap Tms by 7,063.7% in the first quarter. Banque Transatlantique SA now owns 730,699 shares of the medical equipment provider’s stock valued at $1,324,000 after acquiring an additional 720,499 shares during the last quarter. Institutional investors and hedge funds own 62.74% of the company’s stock.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.